Bio Impact Capital LLC Viking Therapeutics, Inc. Transaction History
Bio Impact Capital LLC
- $641 Million
- Q3 2024
A detailed history of Bio Impact Capital LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 120,982 shares of VKTX stock, worth $4.1 Million. This represents 1.19% of its overall portfolio holdings.
Number of Shares
120,982
Previous 118,960
1.7%
Holding current value
$4.1 Million
Previous $6.31 Million
21.46%
% of portfolio
1.19%
Previous 1.01%
Shares
4 transactions
Others Institutions Holding VKTX
# of Institutions
466Shares Held
63.8MCall Options Held
5.76MPut Options Held
3.4M-
Vanguard Group Inc Valley Forge, PA10.2MShares$345 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$204 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$159 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$71.8 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$63.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.6B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...